NT157
目录号 : GC12712
IRS-1/2 抑制剂，抑制 IGF-1R 和 STAT3 信号通路
Cas No.:1384426-12-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 0.3 to 0.8 μM
NT157 is an IRS-1/2 inhibitor.
Insulin receptor substrates 1 and 2 (IRS1/2) mediate antiapoptotic and mitogenic signaling from insulin receptor (IR), insulin-like growth factor 1 receptor (IGF-IR), and other oncoproteins. IRS1 plays a critical role in cancer cell proliferation, and its expression is increased in many human malignancies.
In vitro: NT157 treatment was fonund to be able to lead to dose-dependent suppression of IRS protein expression, inhibition of IGF1R activation, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells. These effects were associated with decreased proliferation, increased apoptosis of LNCaP cells and increased G2-M arrest in PC3 cells. Moreover, NT157 could significantly affect the cell migratory ability, as demonstrated by a wound-healing assay. In addition, the NT157 treatment was able to induce cell cycle arrest and inhibit IGF system signaling [1].
In vivo: In previous animal study, NT157 was found to suppress androgen-responsive growth, delay CRPC progression of LNCaP xenografts, and suppress PC3 tumor growth alone or in combination with docetaxel. This study reported the first preclinical proof-of-principle data that NT157 suppressed IRS1/2 expression, delayed CRPC progression, and suppressed growth of CRPC tumors in vivo [1].
Clinical trial: Up to now, NT157 is still in the preclinical development stage.
Reference:
[1] Ibuki N et al. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. Mol Cancer Ther. 2014 Dec;13(12):2827-39.
| Cas No. | 1384426-12-3 | SDF | |
| 化学名 | (E)-3-(3-bromo-4,5-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide | ||
| Canonical SMILES | OC1=C(O)C=C(/C=C/C(NCC2=CC(O)=C(O)C(O)=C2)=S)C=C1Br | ||
| 分子式 | C16H14BrNO5S | 分子量 | 412.26 |
| 溶解度 | ≥ 50mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4257 mL | 12.1283 mL | 24.2565 mL |
| 5 mM | 0.4851 mL | 2.4257 mL | 4.8513 mL |
| 10 mM | 0.2426 mL | 1.2128 mL | 2.4257 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。